Skip to content
Screener

BioCryst Pharmaceuticals BCRX Raw materials

Raw materials at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$27.85M—
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$374K+320%
Precigen logo
PrecigenPGEN
$333K—
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$4.21M+0.9%
ALN
Alnylam PharmaceuticalsALNY
$13.91M-39.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$610.9M-18.8%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.4B+39.2%
Enterprise value$2.65B+40.4%
P/S2.6×-0.5×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterials.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemJune 30, 2026December 31, 2025
Raw materials$7,852$9,997
Work-in-process25,27312,891
Finished goods6,0437,275
Total inventory39,16830,163
Reserves(1,167)(775)
Total inventory, net$38,001$29,388

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's raw materials?
BioCryst Pharmaceuticals (BCRX) reported raw materials of $7.85M in Q2 2026.
How has BioCryst Pharmaceuticals's raw materials changed year-over-year?
BioCryst Pharmaceuticals's raw materials increased by 8.3% year-over-year, from $7.25M to $7.85M.
What is the long-term trend for BioCryst Pharmaceuticals's raw materials?
Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's raw materials has grown at a 3.9% compound annual growth rate (CAGR), from $8.91M to $10M.
What does raw materials mean?
Unprocessed materials and components purchased for use in manufacturing, valued at cost.

Ask your AI about BioCryst Pharmaceuticals's raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude